Journal
TRENDS IN BIOCHEMICAL SCIENCES
Volume 32, Issue 10, Pages 450-456Publisher
ELSEVIER SCIENCE LONDON
DOI: 10.1016/j.tibs.2007.09.001
Keywords
-
Categories
Funding
- Biotechnology and Biological Sciences Research Council [BBS/B/13330] Funding Source: researchfish
Ask authors/readers for more resources
Owing to its widespread activation in inflammation and cancer, a growing appreciation of the therapeutic potential of inhibitors of the phosphoinositide 3-kinase (PI3K) pathway has stimulated intense interest in compounds with suitable pharmacological profiles. These are primarily directed toward PI3K itself. However, as class I PI3Ks are also essential for a range of normal physiological processes, broad spectrum PI3K inhibition could be poorly tolerated. In recent years, patents describing a new generation of PI3K inhibitors have started to appear, with a particular focus on the development of compounds with enhanced isoform selectivity for use as anti-cancer and anti-inflammatory therapies. However, challenges remain for the efforts to pharmacologically target this enzyme family in a successful manner.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available